8-KShareholder Matters

BOSTON SCIENTIFIC CORP 8-K Report, Shareholder Vote Results (May 6, 2015)

Filed May 6, 2015For Securities:BSX

Summary

Boston Scientific Corporation (BSX) filed an 8-K on May 6, 2015, to report the outcomes of its 2015 Annual Meeting of Stockholders held on May 5, 2015. The primary focus of this filing is the voting results on several key corporate matters. Investors would be interested to know that all director nominees were overwhelmingly re-elected, indicating strong shareholder confidence in the current board's leadership and governance. Furthermore, shareholders provided advisory approval for the compensation of the company's Named Executive Officers, suggesting general satisfaction with executive pay structures. The appointment of Ernst & Young LLP as the independent auditor for the fiscal year 2015 was also ratified with significant support. However, a stockholder proposal concerning accountability in animal use was not approved, reflecting a divergence of opinion on this specific ESG-related matter.

Key Highlights

  • 1All eleven director nominees were elected to the Board of Directors for a one-year term.
  • 2Shareholders approved, on an advisory basis, the compensation of the Named Executive Officers.
  • 3The appointment of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2015 was ratified.
  • 4A stockholder proposal regarding accountability in animal use was not approved by the shareholders.
  • 5The Annual Meeting of Stockholders took place on May 5, 2015, in Marlborough, Massachusetts.
  • 6High levels of 'For' votes were cast for director elections and executive compensation approval, with substantial broker non-votes noted in these categories.

Frequently Asked Questions

This 8-K filing reports the voting results from Boston Scientific Corporation's 2015 Annual Meeting of Stockholders, which took place on May 5, 2015. It details how shareholders voted on director elections, executive compensation, auditor ratification, and a specific stockholder proposal.

All eleven director nominees received a substantial majority of the votes cast 'For' their election, with significant numbers of 'Withheld' votes and 'Broker Non-Votes'. This indicates strong shareholder support for the re-election of the current board members.

Yes, the advisory vote on the compensation for Boston Scientific's Named Executive Officers was approved by the shareholders. This means a majority of the votes cast were in favor of the executive compensation as disclosed in the proxy statement.

The stockholder proposal concerning accountability in animal use was not approved by the shareholders. The voting results show a significantly higher number of 'Against' votes compared to 'For' votes on this particular proposal.